ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-OR19

Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Tuttle, Katherine R., Institute of Translational Health Sciences, Kidney Research Institute, and Nephrology Division, University of Washington, Seattle, Washington, United States
  • Cherney, David, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada
  • Hadjadj, Samy, L'institut du thorax, INSERM, CNRS, University of Nantes, CHU Nantes, Nantes, France
  • Idorn, Thomas, Novo Nordisk A/S, Søborg, Denmark
  • Mosenzon, Ofri, Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel
  • Perkovic, Vlado, University of New South Wales, Sydney, New South Wales, Australia
  • Rasmussen, Soren, Novo Nordisk A/S, Søborg, Denmark
  • Wolthers, Benjamin, Novo Nordisk A/S, Søborg, Denmark
  • Bain, Stephen C., Diabetes Research Unit, Swansea University Medical School, Swansea, United Kingdom
Background

The SUSTAIN 6 cardiovascular outcomes trial (CVOT) indicated that once-weekly (OW) subcutaneous (s.c.) semaglutide may have beneficial effects on kidney function in subjects with type 2 diabetes (T2D) at high CV risk. SUSTAIN 6 and the PIONEER 6 CVOT (once-daily [OD] oral semaglutide) had similar designs and populations, and both evaluated the effects of semaglutide vs placebo (PBO) on macro- and microvascular outcomes. This post hoc analysis of pooled data from the two trials evaluated the effects of semaglutide vs PBO on kidney function decline.

Methods

Data for 6,480 subjects with T2D from SUSTAIN 6 (OW s.c. semaglutide 0.5 and 1.0 mg or PBO, N=3,297; median follow-up 2.1 years) and PIONEER 6 (OD oral semaglutide 14 mg or PBO, N=3,183; median follow-up 1.3 years) were pooled into two groups: semaglutide and PBO. Annual change in estimated glomerular filtration rate (eGFR) was compared (semaglutide vs PBO) in the overall population and subgroups by baseline (BL) eGFR (≥30–<60 or ≥60 mL/min/1.73 m2). Changes in eGFR from BL during trial were analyzed using a linear random regression model with individual intercept and time slope. The estimated treatment difference (ETD) at 1 year between annual rates of eGFR slope from BL was calculated; an interaction p-value <0.05 indicated difference between subgroups.

Results

In the overall population, the annual rate of eGFR change was 0.60 mL/min/1.73 m2 (p<0.0001) lower with semaglutide vs PBO. In the eGFR ≥30–<60 mL/min/1.73 m2 and ≥60 subgroups, the ETDs for semaglutide vs PBO were, respectively, 1.07 and 0.48 mL/min/1.73 m2/year, with a non-significant interaction p-value (Figure).

Conclusion

Semaglutide was associated with a significantly smaller decline in kidney function than PBO in subjects with T2D at high CV risk across tested BL eGFR categories; the data suggest the main benefit might be observed in those with kidney disease.

Funding

  • Commercial Support